JP2015518052A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015518052A5 JP2015518052A5 JP2015515205A JP2015515205A JP2015518052A5 JP 2015518052 A5 JP2015518052 A5 JP 2015518052A5 JP 2015515205 A JP2015515205 A JP 2015515205A JP 2015515205 A JP2015515205 A JP 2015515205A JP 2015518052 A5 JP2015518052 A5 JP 2015518052A5
- Authority
- JP
- Japan
- Prior art keywords
- capsule
- capsule according
- antiprogestin
- weight
- item
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000002775 capsule Substances 0.000 claims description 32
- 230000000708 anti-progestin effect Effects 0.000 claims description 20
- 239000003418 antiprogestin Substances 0.000 claims description 20
- 239000000203 mixture Substances 0.000 claims description 12
- 238000009472 formulation Methods 0.000 claims description 11
- 239000013543 active substance Substances 0.000 claims description 9
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 9
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 claims description 8
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical class C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 claims description 8
- 150000001875 compounds Chemical class 0.000 claims description 8
- 201000009273 Endometriosis Diseases 0.000 claims description 6
- 239000004373 Pullulan Substances 0.000 claims description 6
- 229920001218 Pullulan Polymers 0.000 claims description 6
- 235000019423 pullulan Nutrition 0.000 claims description 6
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 claims description 4
- JVBGZFRPTRKSBB-MJBQOYBXSA-N Telapristone acetate Chemical compound C1([C@@H]2C3=C4CCC(=O)C=C4CC[C@H]3[C@@H]3CC[C@@]([C@]3(C2)C)(C(=O)COC)OC(C)=O)=CC=C(N(C)C)C=C1 JVBGZFRPTRKSBB-MJBQOYBXSA-N 0.000 claims description 4
- 239000000679 carrageenan Substances 0.000 claims description 4
- 235000010418 carrageenan Nutrition 0.000 claims description 4
- 229920001525 carrageenan Polymers 0.000 claims description 4
- 229940113118 carrageenan Drugs 0.000 claims description 4
- 229920002523 polyethylene Glycol 1000 Polymers 0.000 claims description 4
- 239000001103 potassium chloride Substances 0.000 claims description 4
- 235000011164 potassium chloride Nutrition 0.000 claims description 4
- 239000004094 surface-active agent Substances 0.000 claims description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 4
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 claims description 4
- 208000005641 Adenomyosis Diseases 0.000 claims description 3
- 206010008342 Cervix carcinoma Diseases 0.000 claims description 3
- 208000005171 Dysmenorrhea Diseases 0.000 claims description 3
- 206010013935 Dysmenorrhoea Diseases 0.000 claims description 3
- 206010033128 Ovarian cancer Diseases 0.000 claims description 3
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 3
- 208000002193 Pain Diseases 0.000 claims description 3
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims description 3
- 206010046798 Uterine leiomyoma Diseases 0.000 claims description 3
- 201000010881 cervical cancer Diseases 0.000 claims description 3
- 230000001419 dependent effect Effects 0.000 claims description 3
- 201000009274 endometriosis of uterus Diseases 0.000 claims description 3
- 201000010260 leiomyoma Diseases 0.000 claims description 3
- 230000003232 mucoadhesive effect Effects 0.000 claims description 3
- 230000002611 ovarian Effects 0.000 claims description 3
- 239000000186 progesterone Substances 0.000 claims description 3
- 229960003387 progesterone Drugs 0.000 claims description 3
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 claims description 2
- XZIIFPSPUDAGJM-UHFFFAOYSA-N 6-chloro-2-n,2-n-diethylpyrimidine-2,4-diamine Chemical compound CCN(CC)C1=NC(N)=CC(Cl)=N1 XZIIFPSPUDAGJM-UHFFFAOYSA-N 0.000 claims description 2
- 239000004322 Butylated hydroxytoluene Substances 0.000 claims description 2
- NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 claims description 2
- 229920002565 Polyethylene Glycol 400 Polymers 0.000 claims description 2
- 229940095259 butylated hydroxytoluene Drugs 0.000 claims description 2
- 235000010354 butylated hydroxytoluene Nutrition 0.000 claims description 2
- 201000006828 endometrial hyperplasia Diseases 0.000 claims description 2
- 150000002148 esters Chemical class 0.000 claims description 2
- 229940011871 estrogen Drugs 0.000 claims description 2
- 239000000262 estrogen Substances 0.000 claims description 2
- 239000000787 lecithin Substances 0.000 claims description 2
- 235000010445 lecithin Nutrition 0.000 claims description 2
- 229940067606 lecithin Drugs 0.000 claims description 2
- 210000004877 mucosa Anatomy 0.000 claims description 2
- JLFNLZLINWHATN-UHFFFAOYSA-N pentaethylene glycol Chemical compound OCCOCCOCCOCCOCCO JLFNLZLINWHATN-UHFFFAOYSA-N 0.000 claims description 2
- 229920001223 polyethylene glycol Polymers 0.000 claims description 2
- 239000000583 progesterone congener Substances 0.000 claims description 2
- 229940035044 sorbitan monolaurate Drugs 0.000 claims description 2
- 239000003814 drug Substances 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 239000000945 filler Substances 0.000 claims 1
- 230000007170 pathology Effects 0.000 claims 1
- 238000000034 method Methods 0.000 description 22
- 230000006698 induction Effects 0.000 description 2
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 230000002357 endometrial effect Effects 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 230000002175 menstrual effect Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261653674P | 2012-05-31 | 2012-05-31 | |
| US61/653,674 | 2012-05-31 | ||
| PCT/US2013/043447 WO2013181449A1 (en) | 2012-05-31 | 2013-05-30 | Formulations and methods for vaginal delivery of antiprogestins |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015518052A JP2015518052A (ja) | 2015-06-25 |
| JP2015518052A5 true JP2015518052A5 (enExample) | 2016-07-14 |
| JP6341910B2 JP6341910B2 (ja) | 2018-06-13 |
Family
ID=48614182
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015515205A Expired - Fee Related JP6341910B2 (ja) | 2012-05-31 | 2013-05-30 | 抗プロゲスチンの経膣送達用製剤およびその送達方法 |
Country Status (22)
| Country | Link |
|---|---|
| US (1) | US10328022B2 (enExample) |
| EP (1) | EP2854763B1 (enExample) |
| JP (1) | JP6341910B2 (enExample) |
| KR (1) | KR102127348B1 (enExample) |
| CN (1) | CN104334158B (enExample) |
| AU (1) | AU2013267359C1 (enExample) |
| BR (1) | BR112014029131B1 (enExample) |
| CA (1) | CA2872644A1 (enExample) |
| CL (1) | CL2014003232A1 (enExample) |
| CO (1) | CO7141411A2 (enExample) |
| CR (1) | CR20140567A (enExample) |
| EA (1) | EA030444B1 (enExample) |
| ES (1) | ES2701400T3 (enExample) |
| IL (1) | IL235450B (enExample) |
| IN (1) | IN2014DN10548A (enExample) |
| MX (2) | MX363640B (enExample) |
| NZ (1) | NZ702467A (enExample) |
| PH (1) | PH12014502516A1 (enExample) |
| SG (2) | SG10201704858PA (enExample) |
| UA (1) | UA114106C2 (enExample) |
| WO (1) | WO2013181449A1 (enExample) |
| ZA (1) | ZA201408262B (enExample) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HRP20211377T1 (hr) | 2011-11-23 | 2022-01-07 | Therapeuticsmd, Inc. | Prirodne kombinirane hormonske supstitucijske formulacije i terapije |
| US9301920B2 (en) | 2012-06-18 | 2016-04-05 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
| US10806697B2 (en) | 2012-12-21 | 2020-10-20 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US10806740B2 (en) | 2012-06-18 | 2020-10-20 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
| US20150196640A1 (en) | 2012-06-18 | 2015-07-16 | Therapeuticsmd, Inc. | Progesterone formulations having a desirable pk profile |
| US20130338122A1 (en) | 2012-06-18 | 2013-12-19 | Therapeuticsmd, Inc. | Transdermal hormone replacement therapies |
| US11246875B2 (en) | 2012-12-21 | 2022-02-15 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US10537581B2 (en) | 2012-12-21 | 2020-01-21 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US10471072B2 (en) | 2012-12-21 | 2019-11-12 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US10568891B2 (en) | 2012-12-21 | 2020-02-25 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US9180091B2 (en) | 2012-12-21 | 2015-11-10 | Therapeuticsmd, Inc. | Soluble estradiol capsule for vaginal insertion |
| US11266661B2 (en) | 2012-12-21 | 2022-03-08 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| AU2015256473B2 (en) * | 2014-05-05 | 2018-07-12 | Allergan pharmaceuticals International Ltd. | Formulations and methods for vaginal delivery of antiprogestins |
| KR20170005819A (ko) | 2014-05-22 | 2017-01-16 | 쎄러퓨틱스엠디, 인코퍼레이티드 | 천연 복합 호르몬 대체 제형 및 요법 |
| US11623008B2 (en) * | 2014-08-20 | 2023-04-11 | Professional Compounding Centers Of America | Excipient compositions for mucoadhesive pharmaceutical compositions including a synergistic combination of amylopectin, pullulan, hyaluronic acid, and xyloglucan |
| WO2016064873A1 (en) * | 2014-10-20 | 2016-04-28 | Pharmaceutical Manufacturing Research Services, Inc. | Extended release abuse deterrent liquid fill dosage form |
| EP3025709B1 (en) | 2014-11-27 | 2020-09-30 | Capsugel Belgium NV | Dosage form articles for external mucosal applications |
| US10328087B2 (en) | 2015-07-23 | 2019-06-25 | Therapeuticsmd, Inc. | Formulations for solubilizing hormones |
| WO2017173044A1 (en) | 2016-04-01 | 2017-10-05 | Therapeuticsmd Inc. | Steroid hormone compositions in medium chain oils |
| KR20180126582A (ko) | 2016-04-01 | 2018-11-27 | 쎄러퓨틱스엠디, 인코퍼레이티드 | 스테로이드 호르몬 약제학적 조성물 |
| CA3059529A1 (en) | 2017-04-14 | 2018-10-18 | Capsugel Belgium Nv | Process for making pullulan |
| CA3059527A1 (en) | 2017-04-14 | 2018-10-18 | Capsugel Belgium Nv | Pullulan capsules |
Family Cites Families (54)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2377418A1 (fr) | 1977-01-13 | 1978-08-11 | Roussel Uclaf | Nouveaux derives steroides 4,9-dieniques 11b-substitues, leur procede de preparation et leur application comme medicaments |
| FR2521565B1 (fr) | 1982-02-17 | 1985-07-05 | Dior Sa Parfums Christian | Melange pulverulent de constituants lipidiques et de constituants hydrophobes, procede pour le preparer, phases lamellaires lipidiques hydratees et procede de fabrication, compositions pharmaceutiques ou cosmetiques comportant des phases lamellaires lipidiques hydratees |
| FR2522328B1 (fr) | 1982-03-01 | 1986-02-14 | Roussel Uclaf | Nouveaux produits derives de la structure 3-ceto 4,9 19-nor steroides, leur procede de preparation et leur application comme medicaments |
| FR2534487B1 (fr) | 1982-10-15 | 1988-06-10 | Dior Christian Parfums | Procede d'homogeneisation de dispersions de phases lamellaires lipidiques hydratees, et suspensions obtenues par ce procede |
| DE3237814A1 (de) * | 1982-10-12 | 1984-04-12 | Warner-Lambert Co., 07950 Morris Plains, N.J. | Wasserfreie emulsionen und verwendung derselben |
| WO1985002092A1 (en) | 1983-11-14 | 1985-05-23 | Bio-Mimetics Inc. | Bioadhesive compositions and methods of treatment therewith |
| FR2598421B1 (fr) | 1986-05-06 | 1988-08-19 | Roussel Uclaf | Nouveaux produits 19-nor ou 19-nor d-homo steroides substitues en position 11b par un radical phenyle portant un radical alkynyle, leur procede de preparation, leur application comme medicaments et les compositions les renfermant |
| US4954490A (en) | 1988-06-23 | 1990-09-04 | Research Triangle Institute | 11 β-substituted progesterone analogs |
| US5077211A (en) | 1988-07-06 | 1991-12-31 | Applied Genetics, Inc. | Purification and administration of dna repair enzymes |
| US5468741A (en) | 1993-05-28 | 1995-11-21 | The Regents Of The University Of California | Use of low levels of mifepristone to treat leiomyomata |
| US5543150A (en) | 1993-09-15 | 1996-08-06 | Columbia Laboratories, Inc. | Method of progesterone delivery and affect thereof |
| TW385308B (en) * | 1994-03-04 | 2000-03-21 | Merck & Co Inc | Prodrugs of morpholine tachykinin receptor antagonists |
| DE4426601A1 (de) | 1994-07-27 | 1996-02-01 | Schering Ag | Verwendung eines Kombinationsproduktes enthaltend einen kompetitiven Progesteronantagonisten und ein Gestagen zur Herstellung eines Arzneimittels zur Behandlung der Endometriose oder des Leiomyomata uteri |
| CA2186953C (en) | 1995-02-02 | 2009-11-10 | Kristof Chwalsz | Progesterone antagonists for the production of pharmaceutical agents for the treatment of dysfunctional uterine bleeding |
| GB9522403D0 (en) * | 1995-11-01 | 1996-01-03 | Hoechst Roussel Ltd | Intravaginal drug delivery device |
| DE69702450T2 (de) | 1996-05-01 | 2001-03-08 | The Government Of The United States Of America As Represented By The Secretary Of National Institute Of Health, Office Of Technology Transfer | 21-substituierte progesteron derivate als antigestagene |
| US6900193B1 (en) | 1996-05-01 | 2005-05-31 | The United States Of America As Represented By The Department Of Health And Human Services | Structural modification of 19-norprogesterone I: 17-α-substituted-11-β-substituted-4-aryl and 21-substituted 19-norpregnadienedione as new antiprogestational agents |
| WO1998008471A1 (en) | 1996-08-30 | 1998-03-05 | The Population Council, Inc. | Vaginal application mifepristone |
| US6682174B2 (en) | 1998-03-25 | 2004-01-27 | Silverbrook Research Pty Ltd | Ink jet nozzle arrangement configuration |
| US20050070516A1 (en) | 1997-10-28 | 2005-03-31 | Vivus Inc. | As-needed administration of an androgenic agent to enhance female desire and responsiveness |
| US6020328A (en) | 1998-03-06 | 2000-02-01 | Research Triangle Institute | 20-keto-11β-arylsteroids and their derivatives having agonist or antagonist hormonal properties |
| EP1008443A1 (de) | 1998-12-08 | 2000-06-14 | Alusuisse Technology & Management AG | Sterilisierbarer Folienverbund für Verpackungszwecke |
| US6740645B1 (en) | 1999-09-03 | 2004-05-25 | Research Triangle Institute | 17β-acyl-17α-propynyl-11β-(cyclic amino) aryl steroids and their derivatives having antagonist hormonal properties |
| AR025609A1 (es) * | 1999-09-13 | 2002-12-04 | Hoffmann La Roche | Formulaciones lipidas solidas |
| UA74168C2 (uk) | 1999-10-05 | 2005-11-15 | Коламбіа Леборетеріс (Бермуда) Лімітед | Лікування ендометріозу або безпліддя, або покращення плідності та застосування бета-адренергічного агоніста для виробництва лікарського засобу |
| AU2001245849B2 (en) | 2000-03-17 | 2007-01-04 | The Government Of The United States Of America As Represented By The Secretary Of Health And Human Services | Structural modification of 19-norprogesterone i: 17-alpha-substituted-11-beta-substituted-4-aryl and 21-substituted 19-norpregnadienedione as new antiprogestational agents |
| IN191020B (enExample) | 2000-03-28 | 2003-09-13 | Dabur Res Foundation | |
| CZ299942B6 (cs) | 2000-10-18 | 2008-12-29 | Schering Aktiengesellschaft | Farmaceutické prostredky obsahující antiprogestinpro prevenci a lécení hormonálne závislých onemocnení |
| ES2312593T3 (es) | 2001-07-09 | 2009-03-01 | Repros Therapeutics Inc. | Procedimientos y materiales para el tratamiento de la deficiencia de testosterona en hombres. |
| AU2002329842B2 (en) | 2001-08-29 | 2006-09-14 | Umd, Inc. | Vaginal delivery of chemotherapeutic agents and inhibitors of membrane efflux systems for cancer therapy |
| JP2003143474A (ja) | 2001-11-02 | 2003-05-16 | Matsushita Electric Ind Co Ltd | 映像信号処理システム |
| US7417013B2 (en) | 2002-05-01 | 2008-08-26 | Mcneil-Ppc, Inc. | Warming and nonirritating lubricant compositions and method of comparing irritation |
| EP1620060B1 (en) | 2003-04-29 | 2010-03-24 | The General Hospital Corporation | Methods and devices for the sustained release of multiple drugs |
| EP1593376A1 (en) * | 2004-05-04 | 2005-11-09 | Warner-Lambert Company LLC | Improved pullulan capsules |
| CN101080205B (zh) | 2004-07-09 | 2011-10-12 | 人口委员会股份有限公司 | 含孕酮受体调节剂的缓释组合物 |
| GT200500185A (es) | 2004-08-09 | 2006-04-10 | Moduladores del receptor de progesterona que comprenden derivados de pirrol-oxindol y sus usos | |
| MX2007010659A (es) | 2005-03-22 | 2007-11-08 | Repros Therapeutics Inc | Regimenes de dosificacion para trans-clomifeno. |
| CA2604218A1 (en) | 2005-04-20 | 2006-10-26 | Pfizer Limited | Pyrazole derivatives as progesterone receptor antagonists |
| DE102005030294A1 (de) | 2005-06-24 | 2007-01-04 | Schering Ag | Nichtsteroidale Progesteronrezeptor-Modulatoren |
| JP2009510127A (ja) * | 2005-09-29 | 2009-03-12 | リプロス セラピューティクス インコーポレイテッド | ステロイド誘導体および多糖分解されたグリセリドを含む、向上したバイオアベイラビリティーを伴う処方物 |
| CN1846703A (zh) | 2006-02-13 | 2006-10-18 | 程定超 | 米非司酮阴道给药制剂及其组成和制备方法 |
| WO2007103510A2 (en) | 2006-03-08 | 2007-09-13 | Danco Laboratories Llc | Methods, dosing regimens & medications using anti-progestational agents for the treatment of disorders |
| KR20070116538A (ko) * | 2006-06-05 | 2007-12-10 | 유겐가이샤 코리츠 쇼지 | 삽입 보조 기구 |
| JP2008012281A (ja) * | 2006-06-05 | 2008-01-24 | Koritsu Shoji:Kk | 挿入補助器具 |
| CZ300424B6 (cs) * | 2006-06-20 | 2009-05-13 | Pliva - Lachema A. S. | Farmaceutická kompozice pro perorální podání |
| PT3263112T (pt) | 2006-10-24 | 2020-08-25 | Allergan Pharmaceuticals Int Ltd | Composições e métodos para supressão de proliferações do endométrio |
| EP2144601A4 (en) * | 2007-04-05 | 2012-10-10 | Univ Kansas | RAPID DISSOLVING PHARMACEUTICAL COMPOSITIONS COMPRISING PULLULANE |
| EP2148681B1 (en) | 2007-04-20 | 2016-03-16 | PregLem S.A. | Selective progesterone modulators in the treatment of uterine bleeding |
| WO2009037704A1 (en) * | 2007-09-20 | 2009-03-26 | Bio-Pro Medical Ltd. | Compositions and means for treating uterine leiomyomata, leiomyoma, myoma, uterine fibroids, endrometriosis, adenomyosis and related disorders by mifepristone |
| TWI477276B (zh) * | 2008-04-28 | 2015-03-21 | Repros Therapeutics Inc | 抗黃體素給藥方案 |
| EP2482914A1 (en) | 2009-09-29 | 2012-08-08 | Koninklijke Philips Electronics N.V. | Intrauterine electronic capsule for administering a substance |
| UA113283C2 (xx) | 2010-12-23 | 2017-01-10 | 19-норстероїди і їх застосування для лікування прогестеронзалежних станів | |
| DE202011110355U1 (de) | 2011-03-09 | 2014-01-15 | Arstat, Inc. | Behandlung von Uterusmyomen durch intravaginale Verabreichung einer niedrigen Dosis eines selektiven Progesteronrezeptormodulators, eines Antigestagens oder eines Antigestagen-Wirkstoffes |
| UA113291C2 (xx) | 2011-08-04 | 2017-01-10 | Метаболіти транскломіфену і їх застосування |
-
2013
- 2013-05-30 ES ES13728632T patent/ES2701400T3/es active Active
- 2013-05-30 WO PCT/US2013/043447 patent/WO2013181449A1/en not_active Ceased
- 2013-05-30 MX MX2014014054A patent/MX363640B/es unknown
- 2013-05-30 JP JP2015515205A patent/JP6341910B2/ja not_active Expired - Fee Related
- 2013-05-30 SG SG10201704858PA patent/SG10201704858PA/en unknown
- 2013-05-30 IN IN10548DEN2014 patent/IN2014DN10548A/en unknown
- 2013-05-30 CA CA2872644A patent/CA2872644A1/en not_active Abandoned
- 2013-05-30 CN CN201380028413.4A patent/CN104334158B/zh not_active Expired - Fee Related
- 2013-05-30 US US14/403,141 patent/US10328022B2/en not_active Expired - Fee Related
- 2013-05-30 AU AU2013267359A patent/AU2013267359C1/en not_active Ceased
- 2013-05-30 EA EA201492290A patent/EA030444B1/ru unknown
- 2013-05-30 MX MX2019003467A patent/MX382986B/es unknown
- 2013-05-30 NZ NZ702467A patent/NZ702467A/en not_active IP Right Cessation
- 2013-05-30 KR KR1020147032210A patent/KR102127348B1/ko not_active Expired - Fee Related
- 2013-05-30 EP EP13728632.4A patent/EP2854763B1/en active Active
- 2013-05-30 BR BR112014029131-4A patent/BR112014029131B1/pt not_active IP Right Cessation
- 2013-05-30 SG SG11201407397WA patent/SG11201407397WA/en unknown
- 2013-05-30 UA UAA201414106A patent/UA114106C2/uk unknown
-
2014
- 2014-11-02 IL IL235450A patent/IL235450B/en active IP Right Grant
- 2014-11-11 ZA ZA2014/08262A patent/ZA201408262B/en unknown
- 2014-11-11 PH PH12014502516A patent/PH12014502516A1/en unknown
- 2014-11-25 CO CO14259346A patent/CO7141411A2/es unknown
- 2014-11-27 CL CL2014003232A patent/CL2014003232A1/es unknown
- 2014-12-09 CR CR20140567A patent/CR20140567A/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015518052A5 (enExample) | ||
| Kogan et al. | Male contraception: history and development | |
| Burkman et al. | The evolution of combined oral contraception: improving the risk-to-benefit ratio | |
| JP6341910B2 (ja) | 抗プロゲスチンの経膣送達用製剤およびその送達方法 | |
| JP2015520237A5 (enExample) | ||
| JP2017523138A5 (enExample) | ||
| JP2015504924A5 (enExample) | ||
| KR102433001B1 (ko) | 자궁내막증 치료제의 용법·용량 | |
| JP6796693B2 (ja) | 抗プロゲスチンの膣内送達用の製剤と方法 | |
| JP2017514851A5 (enExample) | ||
| EP2779997B1 (en) | Liquid-filled hard gel capsule pharmaceutical formulations | |
| JP2018527305A5 (enExample) | ||
| JP2018140998A5 (enExample) | ||
| JP6335269B2 (ja) | 医薬ソフトゼラチンカプセル剤形 | |
| JP2011507853A5 (enExample) | ||
| JP2015535282A5 (enExample) | ||
| JP2015523388A5 (enExample) | ||
| CN104540497A (zh) | 用于制备治疗子宫内膜异位的含低剂量米非司酮的速释型口服片剂的制剂、如此得到的片剂及其制备方法 | |
| JP2018513174A5 (enExample) | ||
| JP2016527284A5 (enExample) | ||
| Palacios | Which of your patients are ‘not candidates for local oestrogens’? |